PDF(Pubmed)
Abstract：
The treatment landscape for metastatic hormone-sensitive prostate cancer continues to evolve, with systemic treatment being the mainstay of current treatment. Prognostic and predictive factors such as tumour volume and disease presentation have been studied to assess responses to different treatments. Intensification and de-escalation strategies arouse great interest, so several trials are being developed to further personalize the therapy in these populations. Is there an optimal sequence and a possible option to de-intensify treatment in selected patients with a favourable profile? This and other goals will be the subject of this review.
摘要：
转移性激素敏感型前列腺癌的治疗前景继续发展，全身治疗是目前治疗的主要手段。已经研究了预后和预测因素，例如肿瘤体积和疾病表现，以评估对不同治疗的反应。集约化和降级战略引起了极大的兴趣,因此，正在开发一些试验来进一步个性化这些人群的治疗。是否有一个最佳的顺序和一个可能的选择，以减少治疗在选定的患者具有良好的形象？这个和其他目标将是本审查的主题。
